Alkem Laboratories Limited has informed the Exchange about General Updates
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Laboratories has signed a Business Transfer Agreement with its wholly owned subsidiary Alkem Wellness Limited to transfer the company's trade generics business on a slump sale basis. The transfer was first intimated to the exchanges on 10th December 2024, and the agreement has now been executed on 26th September 2025. The transfer will take effect from 1st October 2025. Since Alkem Wellness is a wholly owned subsidiary, the business continues to remain within the Alkem group.
This is an internal group restructuring and does not change the consolidated footprint of Alkem. For shareholders, it means the trade generics business will now be housed in a separate subsidiary, which could allow sharper focus on each segment but will not result in any cash inflow or change in promoter holding.